Want to see OTLC full AI Analyst Report?
OTLC Stock Chart & Stats
$0.08
>-$0.01(-12.62%)
At close: 4:00 PM EST
$0.08
>-$0.01(-12.62%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume643.67K
Average Volume (3M)410.07K
Market Cap
$19.78M
Enterprise Value$16.73T
Total Cash (Recent Filing)$63.61B
Total Debt (Recent Filing)$16.79T
Price to Earnings (P/E)<0.1
Beta-0.04
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.58
Shares Outstanding444,497,300
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap845.74K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda48.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic IP AccessThe Lunai merger gave Oncotelic preferred shares and a broad, perpetual license to exploit transferred IP outside biodefense and Alzheimer’s. That durable access strengthens its R&D platform, reduces time-to-development for follow-ons, and enables licensing or partnering strategies without near-term cash outlay.
GMP Automation PartnershipThe TechForce Robotics collaboration embeds Oncotelic’s AI into GMP-compliant automation, creating a lasting capability to scale regulated manufacturing. This can lower production variability, enable commercial-scale supply, and open a tech-enabled revenue stream beyond drug royalties, strengthening competitive moats.
Pipeline & Manufacturing BreadthOperational progress—combination Phase 1 completion, a Phase 2/3 initiation, multiple Deciparticle programs and an operational GMP facility—builds a diversified clinical and manufacturing base. This reduces reliance on a single asset, supports future commercialization, and increases strategic partnering appeal.
Bears Say
Cash Flow DeficitOperating and free cash flow are structurally negative across reported periods, signaling persistent cash burn and no self-funding path. This forces recurring external financing, constrains sustained R&D investment, increases dilution risk, and limits financial flexibility over the medium term.
Minimal RevenueRevenue is effectively negligible while losses are persistent and margins unsupported. Without meaningful commercial sales, the company's economics depend on binary clinical outcomes, IP monetization, or financing events, making sustainable profitability uncertain and long-term planning challenging.
Dilutive / Costly FinancingThe recent convertible note carries heavy original-issue discount and high cash interest, short maturity and aggressive default terms. This demonstrates reliance on dilutive, expensive private capital and elevates near-term refinancing and shareholder dilution risk, pressuring long-term capital structure stability.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $19.78M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 55 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Currently, no data Available
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 444,497,300 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---